{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:19:51Z","timestamp":1789154391473,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["JA Clin Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy, including low molecular weight heparins (LMWHs) like dalteparin. While LMWHs reduces the risk of HIT compared to unfractionated heparin, vigilance remains essential.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>An 82-year-old male with chronic kidney disease (CKD) developed HIT during hemodialysis anticoagulation with dalteparin, resulting in a platelet count of 17,000\/\u00b5L and positive HIT antibodies. Dalteparin was replaced with nafamostat mesilate. Following confirmed HIT antibody seronegativity, elective aortic valve replacement was performed under cardiopulmonary bypass using heparin. Postoperative dialysis was managed using nafamostat mesilate, preventing HIT recurrence. His platelet count recovered after dalteparin replacement, and no recurrence of HIT was observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Even LMWHs, such as dalteparin, pose a HIT risk, necessitating vigilant monitoring. Confirming HIT antibody seronegativity and appropriately timing surgery are critical for patients with a history of HIT. Proper postoperative follow-up and alternative anticoagulation strategies can prevent HIT recurrence.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40981-025-00781-0","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T19:24:32Z","timestamp":1743189872000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Low molecular weight heparin-induced thrombocytopenia management during hemodialysis and cardiac surgery: a case report and literature review"],"prefix":"10.1186","volume":"11","author":[{"given":"Shuto","family":"Takada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6916-9988","authenticated-orcid":false,"given":"Takahiro","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"781_CR1","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMcp052967","volume":"355","author":"GM Arepally","year":"2006","unstructured":"Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia N Engl J Med. 2006;355:809\u201317. https:\/\/doi.org\/10.1056\/NEJMcp052967.","journal-title":"Heparin-induced thrombocytopenia N Engl J Med"},{"key":"781_CR2","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","volume":"106","author":"N Martel","year":"2005","unstructured":"Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106:2710\u20135. https:\/\/doi.org\/10.1182\/blood-2005-04-1546.","journal-title":"Blood"},{"key":"781_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood.V79.1.1.1","volume":"79","author":"J Hirsh","year":"1992","unstructured":"Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992;79:1\u201317. https:\/\/doi.org\/10.1182\/blood.V79.1.1.1.","journal-title":"Blood"},{"key":"781_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1046\/j.1365-2141.2003.04196.x","volume":"121","author":"RH White","year":"2003","unstructured":"White RH, Ginsberg JS. Low-molecular-weight heparins: are they all the same? Br J Haematol. 2003;121:12\u201320. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04196.x.","journal-title":"Br J Haematol"},{"key":"781_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1055\/s-2008-1066026","volume":"34","author":"WP Jeske","year":"2008","unstructured":"Jeske WP, Walenga JM, Hoppensteadt DA, Vandenberg C, Brubaker A, Adiguzel C, et al. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Semin Thromb Hemost. 2008;34:74\u201385. https:\/\/doi.org\/10.1055\/s-2008-1066026.","journal-title":"Semin Thromb Hemost"},{"key":"781_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23736\/S0392-9590.23.05177-5","volume":"43","author":"AN Nicolaides","year":"2024","unstructured":"Nicolaides AN, Fareed J, Spyropoulos AC, Kakkar RHL, Antignani PL, Avgerinos E, et al. Prevention and management of venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. Int Angiol. 2024;43:1\u2013222. https:\/\/doi.org\/10.23736\/S0392-9590.23.05177-5.","journal-title":"Int Angiol."},{"key":"781_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/01.mcp.0000174232.78219.03","volume":"11","author":"JM Walenga","year":"2005","unstructured":"Walenga JM, Prechel MM, Jeske WP, Bakhos M. Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopenia. Curr Opin Pulm Med. 2005;11:385\u201391. https:\/\/doi.org\/10.1097\/01.mcp.0000174232.78219.03.","journal-title":"Curr Opin Pulm Med"},{"issue":"Suppl 1","key":"781_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1055\/s-2004-823005","volume":"30","author":"JM Walenga","year":"2004","unstructured":"Walenga JM, Jeske WP, Prechel MM, Bacher P, Bakhos M. Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs. Semin Thromb Hemost. 2004;30(Suppl 1):69\u201380. https:\/\/doi.org\/10.1055\/s-2004-823005.","journal-title":"Semin Thromb Hemost"},{"key":"781_CR9","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1111\/jgs.14186","volume":"64","author":"M Giorgi-Pierfranceschi","year":"2016","unstructured":"Giorgi-Pierfranceschi M, Mumoli N, Scarpioni R, Croci E, Dentali F. Argatroban for treatment of heparin-induced thrombocytopenia and thrombosis in a patient with multiple myeloma undergoing hemodialysis. J Am Geriatr Soc. 2016;64:1748\u201350. https:\/\/doi.org\/10.1111\/jgs.14186.","journal-title":"J Am Geriatr Soc"},{"key":"781_CR10","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/ajh.23971","volume":"90","author":"A Tvito","year":"2015","unstructured":"Tvito A, Bakchoul T, Rowe JM, Greinacher A, Ganzel C. Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment. Am J Hematol. 2015;90:675\u20138. https:\/\/doi.org\/10.1002\/ajh.23971.","journal-title":"Am J Hematol"},{"key":"781_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.thromres.2021.09.001","volume":"207","author":"CA Lovatt","year":"2021","unstructured":"Lovatt CA, Crowther MA. Challenging anticoagulation cases: A case of heparin-induced-thrombocytopenia in the first trimester of pregnancy. Thromb Res. 2021;207:58\u201361. https:\/\/doi.org\/10.1016\/j.thromres.2021.09.001.","journal-title":"Thromb Res"},{"key":"781_CR12","doi-asserted-by":"publisher","first-page":"bcr2017221388","DOI":"10.1136\/bcr-2017-221388","volume":"2017","author":"WK Gan","year":"2017","unstructured":"Gan WK. Delayed-onset heparin-induced skin necrosis: a rare complication of perioperative heparin therapy. BMJ Case Rep. 2017;2017:bcr2017221388. https:\/\/doi.org\/10.1136\/bcr-2017-221388.","journal-title":"BMJ Case Rep."},{"key":"781_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/s0272-6386(96)90134-1","volume":"28","author":"S Yamamoto","year":"1996","unstructured":"Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, et al. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis. 1996;28:82\u20135. https:\/\/doi.org\/10.1016\/s0272-6386(96)90134-1.","journal-title":"Am J Kidney Dis"},{"key":"781_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10877-014-9594-2","volume":"29","author":"TE Warkentin","year":"2015","unstructured":"Warkentin TE. 4Ts scoring with hemofiltration or hemodialysis clotting. J Clin Monit Comput. 2015;29:7\u20139. https:\/\/doi.org\/10.1007\/s10877-014-9594-2.","journal-title":"J Clin Monit Comput"},{"key":"781_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/1076029612436676","volume":"19","author":"T Matsuo","year":"2013","unstructured":"Matsuo T, Wanaka K, Walenga JM. Evaluation of circuit and AV fistula clotting and detection of anti-PF4\/heparin complex antibodies in hemodialysis patients suspected of having heparin-induced thrombocytopenia. Clin Appl Thromb Hemost. 2013;19:73\u20138. https:\/\/doi.org\/10.1177\/1076029612436676.","journal-title":"Clin Appl Thromb Hemost"},{"key":"781_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.tmrv.2006.05.001","volume":"20","author":"TE Warkentin","year":"2006","unstructured":"Warkentin TE, Sheppard JAI. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev. 2006;20:259\u201372. https:\/\/doi.org\/10.1016\/j.tmrv.2006.05.001.","journal-title":"Transfus Med Rev"},{"key":"781_CR17","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJM200104263441704","volume":"344","author":"TE Warkentin","year":"2001","unstructured":"Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286\u201392. https:\/\/doi.org\/10.1056\/NEJM200104263441704.","journal-title":"N Engl J Med"},{"key":"781_CR18","doi-asserted-by":"publisher","first-page":"4970","DOI":"10.1182\/blood-2008-08-173062","volume":"113","author":"A Greinacher","year":"2009","unstructured":"Greinacher A, Kohlmann T, Strobel U, Sheppard JAI, Warkentin TE. The temporal profile of the anti-PF4\/heparin immune response. Blood. 2009;113:4970\u20136. https:\/\/doi.org\/10.1182\/blood-2008-08-173062.","journal-title":"Blood"},{"key":"781_CR19","doi-asserted-by":"publisher","first-page":"c149","DOI":"10.1159\/000094960","volume":"104","author":"A Davenport","year":"2006","unstructured":"Davenport A. Hit on dialysis\u2013when is it safe to re-challenge? Nephron Clin Pract. 2006;104:c149\u201350. https:\/\/doi.org\/10.1159\/000094960.","journal-title":"Nephron Clin Pract"},{"key":"781_CR20","doi-asserted-by":"publisher","first-page":"c143","DOI":"10.1159\/000094959","volume":"104","author":"V Hartman","year":"2006","unstructured":"Hartman V, Malbrain M, Daelemans R, Meersman P, Zach\u00e9e P. Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: safety of resuming heparin after disappearance of HIT antibodies. Nephron Clin Pract. 2006;104:c143\u20138. https:\/\/doi.org\/10.1159\/000094959.","journal-title":"Nephron Clin Pract"},{"key":"781_CR21","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1177\/1076029615578167","volume":"21","author":"P Dhakal","year":"2015","unstructured":"Dhakal P, Giri S, Pathak R, Bhatt VR. Heparin reexposure in patients with a history of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost. 2015;21:626\u201331. https:\/\/doi.org\/10.1177\/1076029615578167.","journal-title":"Clin Appl Thromb Hemost"},{"key":"781_CR22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s00540-021-02949-1","volume":"35","author":"T Tamura","year":"2021","unstructured":"Tamura T, Kobayashi E, Kawaguchi M, Matsuoka Y, Fujii A, Ando M, et al. Comparison between the effects of normal saline with and without heparin for the prevention and management of arterial catheter occlusion: a triple-blinded randomized trial. J Anesth. 2021;35:536\u201342. https:\/\/doi.org\/10.1007\/s00540-021-02949-1.","journal-title":"J Anesth"}],"container-title":["JA Clinical Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40981-025-00781-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40981-025-00781-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40981-025-00781-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T19:24:34Z","timestamp":1743189874000},"score":1,"resource":{"primary":{"URL":"https:\/\/jaclinicalreports.springeropen.com\/articles\/10.1186\/s40981-025-00781-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["781"],"URL":"https:\/\/doi.org\/10.1186\/s40981-025-00781-0","relation":{},"ISSN":["2363-9024"],"issn-type":[{"value":"2363-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent to report this case was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}